Survival Outcomes, Prostate-Specific Antigen (PSA) Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Real-World Experience in Hong Kong
Clinical Genitourinary Cancer- United States
doi 10.1016/j.clgc.2018.07.008
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Elsevier BV